Moderna released interim data from the expansion cohort of an ongoing Phase I trial of the company’s mRNA personalized cancer vaccine mRNA-4157, which is being tested in combination with Merck’s checkpoint inhibitor Keytruda (pembrolizumab).
Medidata, a global leader in creating end-to-end solutions to support the entire clinical trial process and a Dassault Systèmes company, announced that Medpace Inc. entered into an agreement to integrate Medidata Rave Imaging with Medpace’s imaging systems and workflow.